Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ketoconazole (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms GreKo
- 21 Jan 2015 Biomarkers information updated
- 01 Sep 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2012-001948-21).
- 17 Aug 2012 Status changed from not yet recruiting to recruiting as reported by EudraCT.